MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR

MATCHING-ADJUSTED INDIRECT COMPARISON OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR

Objectives: Venetoclax-based therapy is a standard option for pts with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor (cBTKi). Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi designed to overcome the pharmacologic lim...

Full description

Bibliographic Details
Main Authors:	O Al-Sawaf, M Jen, LM Hess, J Zhang, B Goebel, JM Pagel, TA Eyre, LYCGN Presenter
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923005370

Similar Items

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY
by: L. E. Roeker, et al.
Published: (2022-06-01)

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
by: A. R. Mato, et al.
Published: (2022-06-01)

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
by: JR Brown, et al.
Published: (2023-10-01)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
by: Jennifer R. Brown, et al.
Published: (2023-08-01)

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
by: NN Shah, et al.
Published: (2023-10-01)

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
by: T. A. Eyre, et al.
Published: (2022-06-01)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
by: T. A. Eyre, et al.
Published: (2022-06-01)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
by: Lydia Scarfò, et al.
Published: (2023-08-01)

P653: OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE
by: T. A. Eyre, et al.
Published: (2022-06-01)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
by: Ester Lovato, et al.
Published: (2023-04-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
by: Rula Zain, et al.
Published: (2021-07-01)

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
by: Alexandra Chirino, et al.
Published: (2023-12-01)

BTK inhibitors approved in Canada for CLL: Strategies for adverse event management
by: Nicole Dunse, et al.
Published: (2021-07-01)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
by: Anna Maria Frustaci, et al.
Published: (2023-02-01)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
by: Alexandra R. Lovell, et al.
Published: (2022-08-01)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
by: Arne Trummer, et al.
Published: (2022-01-01)

P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
by: L. J. Croner, et al.
Published: (2022-06-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
by: Jacopo Olivieri, et al.
Published: (2022-06-01)

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
by: Loïc Ysebaert, et al.
Published: (2023-08-01)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
by: J. P. Sharman, et al.
Published: (2022-06-01)

P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY
by: I. Schwaner, et al.
Published: (2022-06-01)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
by: Marta Sampietro, et al.
Published: (2023-08-01)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
by: Ekaterina Likold, et al.
Published: (2023-08-01)

The potential of pirtobrutinib in multiple B-cell malignancies
by: Jeffrey L. Jensen, et al.
Published: (2022-06-01)

A covalent BTK ternary complex compatible with targeted protein degradation
by: James Schiemer, et al.
Published: (2023-03-01)

P639: OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL-WORLD DATABASE STUDY
by: A. R. Mato, et al.
Published: (2022-06-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
by: Katharine L Lewis, et al.
Published: (2021-08-01)

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
by: Jonathon Cohen, et al.
Published: (2023-08-01)

S140: SINGLE-CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA-PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY
by: R. Thijssen, et al.
Published: (2022-06-01)